MASH is a serious, chronic, and progressive condition that will soon become the leading cause of liver transplantation and a significant contributor to liver cancer development. The FDA’s recent approval of a novel liver-directed therapy (thyroid hormone receptor for the treatment of "at-risk" MASH) presents a much-anticipated opportunity but comes with clinical decision-making challenges for clinicians. This symposium will provide practical, interactive discussions on the use of noninvasive tests (NITs) to identify patients who are most likely to benefit from this new treatment, namely patients with "at-risk" MASH, and those who should not receive this treatment, as well as how to initiate and monitor therapy.
Treating At-Risk MASH: What Are You Waiting For?
Join us for best practices for applying advances in the diagnosis, timelytreatment & management of MASH.
Live
Broadcast
1.00 available credits
Information
January 11, 2025
12:00 PM - 01:00 PM MST
Virtual
Share
This live broadcast will start in exactly:
- 0
Day(s)
- 0
Hour(s)
- 0
Minute(s)
- 0
Second(s)
Share
Share
Share this program on:
Details
Presenters
Comments
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Mazen Noureddin, MD, MHSc
Professor of Clinical Medicine
Lynda K. and David M. Underwood Center for Digestive Disorders
Department of Medicine
Sherrie & Alan Conover Center for Liver Disease & Transplantation
Houston Methodist Research Institute
Houston Methodist Hospital
Houston, TXDr. Noureddin has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Akero, Aligos, Altimmune, AstraZeneca, BI, Boston Pharma, CytoDyn, GSK, Lilly, Madrigal, Merck, Novo Nordisk, Sagimet, Takeda, Terns
Ownership Interest, Stockholder: Akero, ChronWell, CytoDyn, Rivus Pharma
Research: Akero, Allergan, Altimmune, BI, BMS, Boston Pharma, Conatus, Corcept, Enanta, Galectin, Genfit, Gilead, GSK, Kowa, Lilly, Madrigal, Merck, Novartis, Novo Nordisk, Rivus, Shire, Takeda, Terns, Viking, Zydus
Faculty:
Meena B. Bansal, MD, FAASLD
Professor of Medicine
System Chief, Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, NY
Dr. Bansal has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Boston Pharma, Fibronostics, GSK, Intercept, Madrigal, Merck, Novo Nordisk, Pfizer, The Kinetic Group
Research: HistoIndex, Pfizer, Siemens, The Kinetic GroupMary E. Rinella, MD, FAASLD
Professor of Medicine
Director, Metabolic and Fatty Liver Disease
University of Chicago Medicine
Chicago, ILDr. Rinella has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Boehringer Ingelheim, CytoDyn, GSK, HistoIndex, Incyte, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, Sonic, TakedaReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Rosanne Strauss, PharmD, has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Use noninvasive tests (NIT) to identify patients with fibrosis stage 2 or 3 that may benefit from FDA-approved liver-directed treatment
- Use NITs to monitor treatment response to a new approved liver-directed treatment of MASH
- Determine how to use incretin agonists concomitantly in patients being treated with a new liver-directed therapy
- Use noninvasive tests (NIT) to identify patients with fibrosis stage 2 or 3 that may benefit from FDA-approved liver-directed treatment
Target Audience
This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, and endocrinologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in diagnosing, treating, and managing patients with MASH.
Accreditation Statement
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.1 CEUs of pharmacy contact hours. The Universal Activity Number for this program is JA0006235-0000-25-003-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity. Provider
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by an independent educational grant from Madrigal Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this materialis not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Details
Presenters
Comments
Overview
MASH is a serious, chronic, and progressive condition that will soon become the leading cause of liver transplantation and a significant contributor to liver cancer development. The FDA’s recent approval of a novel liver-directed therapy (thyroid hormone receptor for the treatment of "at-risk" MASH) presents a much-anticipated opportunity but comes with clinical decision-making challenges for clinicians. This symposium will provide practical, interactive discussions on the use of noninvasive tests (NITs) to identify patients who are most likely to benefit from this new treatment, namely patients with "at-risk" MASH, and those who should not receive this treatment, as well as how to initiate and monitor therapy.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Mazen Noureddin, MD, MHSc
Professor of Clinical Medicine
Lynda K. and David M. Underwood Center for Digestive Disorders
Department of Medicine
Sherrie & Alan Conover Center for Liver Disease & Transplantation
Houston Methodist Research Institute
Houston Methodist Hospital
Houston, TXDr. Noureddin has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Akero, Aligos, Altimmune, AstraZeneca, BI, Boston Pharma, CytoDyn, GSK, Lilly, Madrigal, Merck, Novo Nordisk, Sagimet, Takeda, Terns
Ownership Interest, Stockholder: Akero, ChronWell, CytoDyn, Rivus Pharma
Research: Akero, Allergan, Altimmune, BI, BMS, Boston Pharma, Conatus, Corcept, Enanta, Galectin, Genfit, Gilead, GSK, Kowa, Lilly, Madrigal, Merck, Novartis, Novo Nordisk, Rivus, Shire, Takeda, Terns, Viking, Zydus
Faculty:
Meena B. Bansal, MD, FAASLD
Professor of Medicine
System Chief, Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, NY
Dr. Bansal has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Boston Pharma, Fibronostics, GSK, Intercept, Madrigal, Merck, Novo Nordisk, Pfizer, The Kinetic Group
Research: HistoIndex, Pfizer, Siemens, The Kinetic GroupMary E. Rinella, MD, FAASLD
Professor of Medicine
Director, Metabolic and Fatty Liver Disease
University of Chicago Medicine
Chicago, ILDr. Rinella has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Boehringer Ingelheim, CytoDyn, GSK, HistoIndex, Incyte, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, Sonic, TakedaReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Rosanne Strauss, PharmD, has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Use noninvasive tests (NIT) to identify patients with fibrosis stage 2 or 3 that may benefit from FDA-approved liver-directed treatment
- Use NITs to monitor treatment response to a new approved liver-directed treatment of MASH
- Determine how to use incretin agonists concomitantly in patients being treated with a new liver-directed therapy
- Use noninvasive tests (NIT) to identify patients with fibrosis stage 2 or 3 that may benefit from FDA-approved liver-directed treatment
Target Audience
This activity has been designed to meet the educational needs of hepatologists, gastroenterologists, and endocrinologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in diagnosing, treating, and managing patients with MASH.
Accreditation Statement
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/0.1 CEUs of pharmacy contact hours. The Universal Activity Number for this program is JA0006235-0000-25-003-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should claim only the credit commensurate with the extent of their participation in the activity. Provider
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by an independent educational grant from Madrigal Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this materialis not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
Ignacio Duran, MD
Wenxin Xu, MD
Sandy Srinivas, MD
1.25 credits 10 episodes
Tanya Dorff, MD
Rana McKay, MD
0.75 credits 7 episodes
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
1.25 program creditsWenxin Xu, MD
Sandy Srinivas, MD
1.25 program creditsClinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
MinuteCE®Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
1.00 program creditNicoletta Colombo, MD
1.00 program credit